Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.51B | $1.60B | $1.72B | $1.84B | $2.15B | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B |
| Revenue growth | — | 6.0% | 7.4% | 7.1% | 16.7% | 31.9% | 2.0% | 2.2% | -1.9% | 6.3% |
| Gross profit | $501M | $513M | $545M | $606M | $768M | $1.18B | $1.14B | $1.13B | $999M | $1.10B |
| Gross margin | 33.2% | 32.1% | 31.8% | 32.9% | 35.8% | 41.5% | 39.4% | 38.3% | 34.5% | 35.9% |
| Operating income | $195M | $226M | $240M | $297M | $407M | $752M | $734M | $676M | $570M | $585M |
| Operating margin | 12.9% | 14.1% | 14.0% | 16.1% | 19.0% | 26.6% | 25.4% | 22.9% | 19.7% | 19.0% |
| Net income | $144M | $151M | $207M | $242M | $346M | $662M | $586M | $593M | $493M | $494M |
| Net margin | 9.5% | 9.4% | 12.0% | 13.1% | 16.1% | 23.4% | 20.3% | 20.1% | 17.0% | 16.1% |
| EPS (diluted) | $1.91 | $1.99 | $2.74 | $3.21 | $4.57 | $8.67 | $7.73 | $7.88 | $6.69 | $6.79 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $219M | $263M | $289M | $367M | $473M | $584M | $724M | $777M | $653M | $755M |
| Capital expenditures | $170M | $131M | $105M | $126M | $174M | $253M | $285M | $362M | $377M | $286M |
| Free cash flow | $49.2M | $133M | $184M | $241M | $298M | $331M | $439M | $415M | $276M | $469M |
| Share buybacks | $52.2M | $74.4M | $70.8M | $83.1M | $116M | $137M | $203M | $438M | $561M | $134M |
| Dividends paid | $35.8M | $39.1M | $42.1M | $45.1M | $48.1M | $51.1M | $54.1M | $57.0M | $59.1M | $61.2M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $203M | $236M | $337M | $439M | $616M | $763M | $894M | $854M | $485M | $791M |
| Total assets | $1.72B | $1.86B | $1.98B | $2.34B | $2.79B | $3.31B | $3.62B | $3.83B | $3.64B | $4.27B |
| Total liabilities | $599M | $583M | $583M | $768M | $939M | $978M | $932M | $949M | $961M | $1.09B |
| Long-term debt | $226M | $197M | $196M | $255M | $253M | $209M | $207M | $72.8M | $203M | $203M |
| Shareholders' equity | $1.12B | $1.28B | $1.40B | $1.57B | $1.85B | $2.34B | $2.68B | $2.88B | $2.68B | $3.18B |
| Retained earnings | $1.07B | $1.18B | $1.35B | $1.55B | $1.85B | $2.46B | $2.99B | $3.52B | $3.96B | $4.37B |
| Shares (wtd avg diluted) | 75.0M | 75.8M | 75.4M | 75.4M | 75.8M | 76.3M | 75.8M | 75.3M | 73.7M | 72.7M |
Every figure is extracted from WEST PHARMACEUTICAL SERVICES INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.